JP2022515239A - 有機化合物の結晶および塩形態およびその医薬組成物 - Google Patents

有機化合物の結晶および塩形態およびその医薬組成物 Download PDF

Info

Publication number
JP2022515239A
JP2022515239A JP2021536323A JP2021536323A JP2022515239A JP 2022515239 A JP2022515239 A JP 2022515239A JP 2021536323 A JP2021536323 A JP 2021536323A JP 2021536323 A JP2021536323 A JP 2021536323A JP 2022515239 A JP2022515239 A JP 2022515239A
Authority
JP
Japan
Prior art keywords
weight
cancer
pharmaceutical composition
compound
tris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021536323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515239A5 (enExample
Inventor
アルタフ，サイード
ラマクリシュナン，アビラ
サイズモア，ジェイコブ
ジャーン，シジエ
Original Assignee
レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ filed Critical レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ
Publication of JP2022515239A publication Critical patent/JP2022515239A/ja
Publication of JP2022515239A5 publication Critical patent/JP2022515239A5/ja
Priority to JP2024131002A priority Critical patent/JP7749080B2/ja
Priority to JP2025156833A priority patent/JP2026001058A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021536323A 2018-12-21 2019-12-20 有機化合物の結晶および塩形態およびその医薬組成物 Pending JP2022515239A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024131002A JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物
JP2025156833A JP2026001058A (ja) 2018-12-21 2025-09-22 有機化合物の結晶および塩形態およびその医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US62/784,083 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US62/791,571 2019-01-11
US201962882712P 2019-08-05 2019-08-05
US62/882,712 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024131002A Division JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物

Publications (2)

Publication Number Publication Date
JP2022515239A true JP2022515239A (ja) 2022-02-17
JP2022515239A5 JP2022515239A5 (enExample) 2022-12-26

Family

ID=69185721

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021536323A Pending JP2022515239A (ja) 2018-12-21 2019-12-20 有機化合物の結晶および塩形態およびその医薬組成物
JP2024131002A Active JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物
JP2025156833A Pending JP2026001058A (ja) 2018-12-21 2025-09-22 有機化合物の結晶および塩形態およびその医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024131002A Active JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物
JP2025156833A Pending JP2026001058A (ja) 2018-12-21 2025-09-22 有機化合物の結晶および塩形態およびその医薬組成物

Country Status (23)

Country Link
US (2) US12297179B2 (enExample)
EP (1) EP3898597A1 (enExample)
JP (3) JP2022515239A (enExample)
KR (1) KR20220035022A (enExample)
CN (1) CN113508108B (enExample)
AU (1) AU2019403396B2 (enExample)
BR (1) BR112021012305A2 (enExample)
CA (1) CA3124401A1 (enExample)
CL (1) CL2021001640A1 (enExample)
CO (1) CO2021009309A2 (enExample)
CR (1) CR20210394A (enExample)
GE (2) GEAP202415700A (enExample)
IL (1) IL284218B1 (enExample)
JO (1) JOP20210147A1 (enExample)
MA (1) MA54541A (enExample)
MX (1) MX2021007536A (enExample)
NI (1) NI202100055A (enExample)
PE (2) PE20212197A1 (enExample)
PH (1) PH12021551495A1 (enExample)
SG (1) SG11202106526UA (enExample)
TW (1) TWI875727B (enExample)
UA (1) UA130491C2 (enExample)
WO (1) WO2020132471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510352A (ja) * 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
JP2012520251A (ja) * 2009-03-13 2012-09-06 アルミラル・ソシエダッド・アノニマ Ｄｈｏｄｈ阻害剤としての、トロメタミンとアザビフェニルアミノ安息香酸誘導体の付加塩
JP2012520252A (ja) * 2009-03-13 2012-09-06 アルミラル・ソシエダッド・アノニマ Ｄｈｏｄｈ阻害剤としての、ヒドロキシル基および／またはカルボキシル基含有アミンとアミノニコチン酸誘導体との付加塩
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
US9012464B2 (en) * 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
TWI818954B (zh) * 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
CA3184024A1 (en) * 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510352A (ja) * 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
JP2012520251A (ja) * 2009-03-13 2012-09-06 アルミラル・ソシエダッド・アノニマ Ｄｈｏｄｈ阻害剤としての、トロメタミンとアザビフェニルアミノ安息香酸誘導体の付加塩
JP2012520252A (ja) * 2009-03-13 2012-09-06 アルミラル・ソシエダッド・アノニマ Ｄｈｏｄｈ阻害剤としての、ヒドロキシル基および／またはカルボキシル基含有アミンとアミノニコチン酸誘導体との付加塩
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BASTIN, R. J. ET AL: ""Salt selection and optimization procedures for pharmaceutical new chemical entities"", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, no. 5, JPN6009059058, 2000, pages 427 - 435, ISSN: 0005184011 *
長瀬 博 監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), pages 347 - 365, ISSN: 0005299125 *

Also Published As

Publication number Publication date
NI202100055A (es) 2021-12-01
MX2021007536A (es) 2021-09-23
BR112021012305A2 (pt) 2021-10-05
GEAP202415700A (en) 2024-05-13
JP7749080B2 (ja) 2025-10-03
TWI875727B (zh) 2025-03-11
CA3124401A1 (en) 2020-06-25
CN113508108B (zh) 2024-12-24
AU2019403396A1 (en) 2021-07-08
CL2021001640A1 (es) 2022-06-03
CN113508108A (zh) 2021-10-15
JOP20210147A1 (ar) 2023-01-30
KR20220035022A (ko) 2022-03-21
US12297179B2 (en) 2025-05-13
IL284218A (en) 2021-08-31
WO2020132471A1 (en) 2020-06-25
US20250270175A1 (en) 2025-08-28
PH12021551495A1 (en) 2022-03-07
JP2026001058A (ja) 2026-01-06
SG11202106526UA (en) 2021-07-29
UA130491C2 (uk) 2026-03-04
CO2021009309A2 (es) 2021-10-29
WO2020132471A8 (en) 2020-08-06
PE20212197A1 (es) 2021-11-16
PE20260309A1 (es) 2026-02-11
AU2019403396B2 (en) 2024-12-12
GEP20247683B (en) 2024-10-28
EP3898597A1 (en) 2021-10-27
MA54541A (fr) 2022-03-09
JP2024161431A (ja) 2024-11-19
US20220055995A1 (en) 2022-02-24
TW202039448A (zh) 2020-11-01
IL284218B1 (en) 2026-01-01
CR20210394A (es) 2021-12-13

Similar Documents

Publication Publication Date Title
JP7749080B2 (ja) 有機化合物の結晶および塩形態およびその医薬組成物
JP6737838B2 (ja) Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤
CN115300513A (zh) 一种包含杂环类shp2抑制剂的组合物及其用途
KR101668497B1 (ko) 메틸모르폴린-치환된 피리도 [2,3-ｄ] 피리미딘의 제조 방법 및 이를 포함하는 조성물
CN119350242A (zh) 靶向krasg12d的取代喹啉酮类化合物及其应用
JP2015500219A (ja) 新規な結晶形を有するチカグレロル及びその調製方法
CN115175904A (zh) Ezh2抑制剂的结晶氢溴酸盐、其制备和用于治疗癌症的药物组合物
US11713309B2 (en) Solid forms of Cerdulatinib
JP4548884B2 (ja) ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン誘導体
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
CN109512823B (zh) 一种包含取代嘧啶类pi3k抑制剂的组合物及其用途
EA045339B1 (ru) Кристаллические и солевые формы органического соединения и их фармацевтические композиции
TW202227446A (zh) 有機化合物之固態形式
OA20637A (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof.
WO2011027988A2 (en) Novel polymorphic form of prasugrel-hydrogen sulfate
CN114957137B (zh) N-(1,2,3,6-四氢嘧啶-4-基)-2-苯基乙酰胺类化合物及其制备与应用
WO2025231052A1 (en) Solid dispersions of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2- methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
CN121039127A (zh) 具有刺猬通路拮抗剂活性手性杂环化合物的盐型及其晶型
HK40116388A (zh) 用作cdk7激酶抑制剂的化合物及其应用
JP2023532209A (ja) 経口製剤およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240408